Adimab announced a multi-target discovery and optimization collaboration with Sanofi.
Adimab will use its proprietary platform to generate bispecific molecules against multiple targets.
Sanofi will have the right to develop and commercialize all therapeutic antibodies and bispecifics resulting from the collaboration.
|Searching for more deal information? Current Partnering offers the following options:
Adimab and Sanofi have entered into a collaboration whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies or bispecifics against multiple targets.
For each project, the agreement grants Sanofi the right to research antibodies and bispecifics generated during the collaboration for potential use as therapeutic products.
Adimab will receive an undisclosed upfront payment, research fees and technical milestones.
In addition, for each target, Sanofi will have the option to exclusively license antibodies and bispecifics generated during the collaboration.
If Sanofi exercises its option for a particular therapeutic lead, Adimab would receive license fees, clinical milestones and royalties on product sales.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies